| James Eric Theisen, MD | |
|
5201 Harry Hines Blvd, House Staff & Gme, Dallas, TX 75235-7708 | |
| (214) 590-8058 | |
| Not Available |
| Full Name | James Eric Theisen |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 22 Years |
| Location | 5201 Harry Hines Blvd, Dallas, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104027986 | NPI | - | NPPES |
| BP1-0026367 | Other | INSTITUTIONAL PERMIT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | M9049 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Parkland Health & Hospital System | Dallas, TX | Hospital |
| Ut Southwestern University Hospital - William P. Clements Jr. | Dallas, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Texas Southwestern Medical Center | 0648188250 | 2588 |
News Archive
For the first time, researchers have shown that a chemotherapy regimen of capecitabine plus oxaliplatin (CAPOX) is as safe and effective as infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) in the first-line treatment of metastatic colorectal carcinoma (MCRC).
Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced it has launched new education, distribution, sampling and reimbursement programs for TIMOPTIC(R) in OCUDOSE(R), the only preservative-free medication for glaucoma available in the United States. Aton acquired the U.S. marketing rights in February to the TIMOPTIC product line from Merck & Co., Inc. TIMOPTIC (timolol maleate) is a non-selective beta-adrenergic receptor blocking agent indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. As many as 2.25 million Americans suffer from open-angle glaucoma.
Researchers at University of California San Diego School of Medicine have launched a first-in-human Phase I clinical trial to assess the safety and efficacy of a gene therapy to deliver a key protein into the brains of persons with Alzheimer's disease (AD) or Mild Cognitive Impairment (MCI), a condition that often precedes full-blown dementia.
Three national nursing organizations today announced a collaborative effort to transform the care and culture of serious illness in the United States.
Tarix Pharmaceuticals today announced enrollment of the first patient in a Phase 2 clinical study of TXA127, a pharmaceutical grade formulation of a naturally occurring peptide known to stimulate early hematopoietic precursor cells in the bone marrow.
› Verified 2 days ago
| Entity Name | University Of Texas Southwestern Medical Center At Dallas |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972579365 PECOS PAC ID: 0648188250 Enrollment ID: O20031106000792 |
News Archive
For the first time, researchers have shown that a chemotherapy regimen of capecitabine plus oxaliplatin (CAPOX) is as safe and effective as infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) in the first-line treatment of metastatic colorectal carcinoma (MCRC).
Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced it has launched new education, distribution, sampling and reimbursement programs for TIMOPTIC(R) in OCUDOSE(R), the only preservative-free medication for glaucoma available in the United States. Aton acquired the U.S. marketing rights in February to the TIMOPTIC product line from Merck & Co., Inc. TIMOPTIC (timolol maleate) is a non-selective beta-adrenergic receptor blocking agent indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. As many as 2.25 million Americans suffer from open-angle glaucoma.
Researchers at University of California San Diego School of Medicine have launched a first-in-human Phase I clinical trial to assess the safety and efficacy of a gene therapy to deliver a key protein into the brains of persons with Alzheimer's disease (AD) or Mild Cognitive Impairment (MCI), a condition that often precedes full-blown dementia.
Three national nursing organizations today announced a collaborative effort to transform the care and culture of serious illness in the United States.
Tarix Pharmaceuticals today announced enrollment of the first patient in a Phase 2 clinical study of TXA127, a pharmaceutical grade formulation of a naturally occurring peptide known to stimulate early hematopoietic precursor cells in the bone marrow.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| James Eric Theisen, MD 5201 Harry Hines Blvd, House Staff & Gme, Dallas, TX 75235-7708 Ph: (214) 590-8058 | James Eric Theisen, MD 5201 Harry Hines Blvd, House Staff & Gme, Dallas, TX 75235-7708 Ph: (214) 590-8058 |
News Archive
For the first time, researchers have shown that a chemotherapy regimen of capecitabine plus oxaliplatin (CAPOX) is as safe and effective as infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) in the first-line treatment of metastatic colorectal carcinoma (MCRC).
Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced it has launched new education, distribution, sampling and reimbursement programs for TIMOPTIC(R) in OCUDOSE(R), the only preservative-free medication for glaucoma available in the United States. Aton acquired the U.S. marketing rights in February to the TIMOPTIC product line from Merck & Co., Inc. TIMOPTIC (timolol maleate) is a non-selective beta-adrenergic receptor blocking agent indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. As many as 2.25 million Americans suffer from open-angle glaucoma.
Researchers at University of California San Diego School of Medicine have launched a first-in-human Phase I clinical trial to assess the safety and efficacy of a gene therapy to deliver a key protein into the brains of persons with Alzheimer's disease (AD) or Mild Cognitive Impairment (MCI), a condition that often precedes full-blown dementia.
Three national nursing organizations today announced a collaborative effort to transform the care and culture of serious illness in the United States.
Tarix Pharmaceuticals today announced enrollment of the first patient in a Phase 2 clinical study of TXA127, a pharmaceutical grade formulation of a naturally occurring peptide known to stimulate early hematopoietic precursor cells in the bone marrow.
› Verified 2 days ago
Lee M. Lunsford, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-648-8000 | |
Dr. Stephanie C Jones, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-648-9374 | |
Dr. Alfredo Ruben Lopez, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 6606 Lbj Fwy Ste 200, Dallas, TX 75240 Phone: 972-715-5000 Fax: 972-715-9976 | |
Dr. Elvis Tsang, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 12222 Merit Dr Ste 600, Dallas, TX 75251 Phone: 972-715-5000 Fax: 972-715-9976 | |
Dr. Christopher D Lecheminant, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 6606 Lbj Fwy Ste 200, Dallas, TX 75240 Phone: 972-715-5000 | |
Dr. Mihir N Rane, D.O. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3625 N Hall St Ste 800, Dallas, TX 75219 Phone: 214-252-3500 | |
Lisa Gu, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-648-6400 |